Mirvetuximab and Emerging ADCs Should Define Treatment Selection by Biomarker

This session will examine treatment selection in recurrent ovarian cancer in the era of antibody-drug conjugates (ADCs). Faculty will compare biomarker-driven use of agents such as mirvetuximab with traditional platinum-based sequencing strategies, reviewing clinical evidence, resistance patterns, and practical considerations. Participants will gain insight into how emerging therapies may reshape decision-making. This discussion will focus on the growing role of ADCs, including mirvetuximab, as biomarker-selected therapies. Faculty will review clinical trial data supporting improved outcomes in target-expressing populations and discuss how biomarker testing can guide treatment selection, improve precision, and potentially shift sequencing paradigms.